Clinical trial
Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)
NCT00475098 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00475098 |
|---|---|
| Title | Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT) |
| Official title | Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial. |
| Acronym | TILT |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Tinzaparin sodium 100 UI/Kg/OD for 12 weeks |
| Enrollment | 553 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2016 |
| Completion | Aug 1, 2016 |
| First posted | May 17, 2007 |
| Last update posted | Sep 2, 2016 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: